| Identification | Back Directory | [Name]
Larazotide | [CAS]
881851-50-9 | [Synonyms]
Larazotide acetate
LARAZOTIDE ACETATE (> 90%)
H-GLY-GLY-VAL-LEU-VAL-GLN-PRO-GLY-OH | [Molecular Formula]
C34H59N9O12 | [MDL Number]
MFCD31630844 | [MOL File]
881851-50-9.mol | [Molecular Weight]
785.885 |
| Chemical Properties | Back Directory | [Melting point ]
>231°C (dec.) | [storage temp. ]
Refrigerator | [solubility ]
Water (Slightly) | [form ]
Solid | [color ]
White | [InChIKey]
NYGCNONRVCGHAT-FTIBEKKFNA-N | [SMILES]
C(O)(=O)C.C(O)(=O)CNC([C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(CNC(CN)=O)=O)C(C)C)CC(C)C)C(C)C)CCC(N)=O)=O |&1:10,17,21,25,29,r| |
| Hazard Information | Back Directory | [Uses]
Larazotide Acetate is a selective α3β4* neuronal nicotinic ACh receptor antagonist. | [Biological Activity]
Larazotide acetate (AT1001) is a Zonulin receptor antagonista tight junction modulator. Larazotide inhibition of zonulin results in reducing trafficking across epithelial cells in the intestines and reducing intestinal permeability and "leaky gut," thought to be a gateway to multiple autoimmune diseasesincluding celiac diseaseirritable bowel syndrome (IBS)inflammatory bowel diseases (IBDCrohnμs and ulcerative colitis)type 1 diabetes mellitus (T1DM)nonalcoholic steatohepatitis (NASH)chronic kidney disease (CKD) and several others. It has been shown to inhibit the effect of inflammatory cytokines such as tumor necrosis factor (TNF-alpha) and interleukin (IL-4)blocking their increase of intestinal epithelial permeability. | [in vivo]
Larazotide acetate (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice[1]. | Animal Model: | HLA-HCD4/DQ8 double transgenic mice[2] | | Dosage: | 250 μg | | Administration: | Intraperitoneal injection; 250 μg twice a week for 7 weeks | | Result: | Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels.
|
| [storage]
Store at -20°C |
|
|